Afterwards, WB was used to check the inhibitory effects of Src activity by dasatinib in HT29 and SW480 cells, indicating that dasatinib suppressed Src activity in a time- and concentration-dependent pattern in colon cancer cells. Here, SRC is linked to malignant colon neoplasm.